Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 1.00 |
| ▸ | AHR | P35869 | 5/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-Naphthoflavone SCHEMBL43538 | 1.00 | ABCG2 (1.00) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| Beta-Naphthoflavone SCHEMBL29881204 | 1.00 | ABCG2 (1.00) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| Alpha-Naphthoflavone SCHEMBL3665037 | 0.90 | CYP1A1 (0.82) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| SCHEMBL15397111 | 0.88 | AHR (0.78) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| SCHEMBL13066020 | 0.88 | TDP1 (1.00) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| SCHEMBL25109125 | 0.84 | AHR (0.72) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| SCHEMBL15397001 | 0.84 | AHR (0.72) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| SCHEMBL22525848 | 0.84 | AHR (0.72) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| SCHEMBL29361866 | 0.84 | TDP1 (0.74) | ABCG2AHRCYP1A1CYP1A2PAX8 | |
| SCHEMBL7116289 | 0.84 | ABCG2 (1.00) | ABCG2AHRCYP1A1CYP1A2PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596657-B2 | Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2023-03-07 | — | — | US | claimed |
| US-20220273610-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-09-01 | — | — | US | claimed |
| US-20220143143-A1 | USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES | UNIV MCMASTER (CA) | 2022-05-12 | — | — | US | claimed |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | BECKLEY PSYTECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260035334-A1 | METHOD OF SYNTHESIS | BECKLEY PSYTECH LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| WO-2025235664-A1 | PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-3522902-B1 | PROBIOTIC BACTERIA PRODUCING AN AHR AGONIST AND THEIR USE IN THE TREATMENT OF METABOLIC SYNDROME AND OBESITY | INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT (FR) | 2025-09-03 | — | — | EP | disclosed |
| EP-4595962-A2 | PHARMACEUTICAL COMPOSITION | Beckley Psytech Limited (GB) | 2025-08-06 | — | — | EP | disclosed |
| EP-4551940-A2 | METHODS AND ASSAYS FOR SECRETOME ACTIVITY ANALYSIS | Combangio, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4483957-A2 | PHARMACEUTICAL COMPOSITION | Beckley Psytech Limited (GB) | 2025-01-01 | — | — | EP | disclosed |
| EP-4463158-A2 | NOVEL PRODRUGS DERIVED FROM NICOTINIC ACID AND RIBOSE | Mitopower, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-11518743-B2 | Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine | Beckley Psytech Limited (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11518742-B2 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine | Beckley Psytech Limited (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20220273610-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-09-01 | — | — | US | disclosed |
| US-20220267267-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Beckley Psytech Limited (GB) | 2022-08-25 | — | — | US | disclosed |
| US-20220259147-A1 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Beckley Psytech Limited (GB) | 2022-08-18 | — | — | US | disclosed |
| EP-4034536-A1 | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| US-20220143143-A1 | USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES | UNIV MCMASTER (CA) | 2022-05-12 | — | — | US | disclosed |
| WO-2022082106-A1 | PEST REPELLENTS AND USES THEREOF | Sensorygen, Inc. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3941583-A1 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Beckley Psytech Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259147-A1 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | HTR5A, SLC6A4, HTR4 | ABCG2 261/4885AHR 1338/4885CYP1A1 798/4885 |
| US-20260035334-A1 | METHOD OF SYNTHESIS | HTR5A, HTR1A, HTR2C | ABCG2 481/4885AHR 1328/4885CYP1A1 541/4885 |
| US-20220273610-A1 | ANTIMYCOTIC | ETF1, API5, ERG28 | ABCG2 388/4885AHR 1952/4885CYP1A1 1358/4885 |
| US-11518742-B2 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine | HTR5A, SLC6A4, HTR4 | ABCG2 261/4885AHR 1338/4885CYP1A1 798/4885 |
| US-20220267267-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | HTR5A, INMT, HTR1A | ABCG2 356/4885AHR 2496/4885CYP1A1 603/4885 |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | HTR5A, PNMT, NPY5R | ABCG2 2345/4885AHR 2328/4885CYP1A1 2750/4885 |
| US-11518743-B2 | Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine | HTR5A, INMT, HTR1A | ABCG2 356/4885AHR 2496/4885CYP1A1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.